文献速递神经MR

深度学习能否在神经肿瘤学中替代钆对比剂:一项阅片者研究

Can Deep Learning Replace Gadolinium in Neuro-Oncology?: A Reader Study.
PubMed 文献 · Invest Radiol · 2022-01-01

这项单中心回顾性研究基于200例多参数脑MRI,训练深度学习网络用平扫和低剂量序列预测虚拟增强T1图像,并在38例独立测试样本中评估。自动分析显示虚拟序列与标准增强T1的结构相似指数为87.1%±4.8%、AUC为96.4%±3.1%,阅片者研究显示虚拟图像质量评分优于标准剂量MRI(P=0.008);大于10 mm病灶平均敏感度83%,但包含更小病灶时敏感度降至67%和56%,作者结论认为全剂量注射对神经肿瘤一线准确诊断仍不可或缺。

要点

  • 虚拟增强T1与标准增强T1的结构相似指数为87.1%±4.8%,体素敏感度96.4%、特异度94.8%。
  • 大于10 mm病灶平均敏感度83%,大于5 mm为67%,所有病灶为56%。
  • 阅片者认为虚拟图像质量优于标准剂量MRI(P=0.008)。

核心结论

  • 深度学习预测虚拟增强T1脑MRI在体素级指标上表现很高,大于10 mm病灶在对比剂用量减少4倍时仍维持良好检出,但小病灶处理困难,全剂量注射对神经肿瘤一线准确诊断仍不可或缺。

研究设计与样本

  • 单中心回顾性研究,纳入200例多参数脑MRI、145例患者,训练样本107例(55±14岁,58例女性),独立测试样本38例(62±12岁,22例女性),设备序列包括T1、T2-FLAIR、扩散加权成像、低剂量和标准剂量增强后T1序列。

关键影像表现/征象

  • 虚拟增强T1与参考增强T1的结构相似指数为87.1%±4.8%,峰值信噪比为31.6±2.0 dB。
  • 测试样本38例增强T1序列共识别91个参考病灶。
  • 大于10 mm病灶(n=42)平均敏感度83%,假检出率0.08病灶/患者,阳性预测值92%,F1评分88%。
  • 大于5 mm病灶(n=74)平均敏感度67%,所有病灶平均敏感度56%,假检出率均低于0.50病灶/患者,阳性预测值均高于73%,F1评分最差为63%。

诊断标准与关键数值

  • 自动分析虚拟序列与参考增强T1的AUC为96.4%±3.1%,在Youden工作点体素敏感度96.4%、特异度94.8%。
  • 阅片者研究采用2名放射科医生对图像质量评分并标记所有可见强化病灶。
  • 病灶检出敏感度按病灶大小分层:大于10 mm为83%(n=42),大于5 mm为67%(n=74),所有病灶为56%。

临床应用与阅片要点

  • 虚拟图像在图像质量上被阅片者偏好于标准剂量MRI(P=0.008)。
  • 大于10 mm病灶在对比剂用量减少4倍时检出性能仍可维持。
  • 小病灶对深度网络处理困难,全剂量注射对神经肿瘤一线准确诊断仍不可或缺。

局限性

  • 小病灶被证明难以被深度网络处理。
  • 全剂量注射对神经肿瘤一线准确诊断仍不可或缺。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

MATERIALS AND METHODS: This monocentric retrospective study leveraged 200 multiparametric brain MRIs acquired between November 2019 and February 2020 at Gustave Roussy Cancer Campus (Villejuif, France). A total of 145 patients were included: 107 formed the training sample (55 ± 14 years, 58 women) and 38 the separate test sample (62 ± 12 years, 22 women). Patients had glioma, brain metastases, meningioma, or no enhancing lesion. T1, T2-FLAIR, diffusion-weighted imaging, low-dose, and standard-dose postcontrast T1 sequences were acquired. A deep network was trained to process the precontrast and low-dose sequences to predict "virtual" surrogate images for contrast-enhanced T1. Once trained, the deep learning method was evaluated on the test sample. The discrepancies between the predicted virtual images and the standard-dose MRIs were qualitatively and quantitatively evaluated using both automated voxel-wise metrics and a reader study, where 2 radiologists graded image qualities and marked all visible enhancing lesions.

RESULTS: The automated analysis of the test brain MRIs computed a structural similarity index of 87.1% ± 4.8% between the predicted virtual sequences and the reference contrast-enhanced T1 MRIs, a peak signal-to-noise ratio of 31.6 ± 2.0 dB, and an area under the curve of 96.4% ± 3.1%. At Youden's operating point, the voxel-wise sensitivity (SE) and specificity were 96.4% and 94.8%, respectively. The reader study found that virtual images were preferred to standard-dose MRI in terms of image quality (P = 0.008). A total of 91 reference lesions were identified in the 38 test T1 sequences enhanced with full dose of contrast agent. On average across readers, the brain lesion SE of the virtual images was 83% for lesions larger than 10 mm (n = 42), and the associated false detection rate was 0.08 lesion/patient. The corresponding positive predictive value of detected lesions was 92%, and the F1 score was 88%. Lesion detection performance, however, dropped when smaller lesions were included: average SE was 67% for lesions larger than 5 mm (n = 74), and 56% with all lesions included regardless of their size. The false detection rate remained below 0.50 lesion/patient in all cases, and the positive predictive value remained above 73%. The composite F1 score was 63% at worst.

CONCLUSIONS: The proposed deep learning method for virtual contrast-enhanced T1 brain MRI prediction showed very high quantitative performance when evaluated with standard voxel-wise metrics. The reader study demonstrated that, for lesions larger than 10 mm, good detection performance could be maintained despite a 4-fold division in contrast agent usage, unveiling a promising avenue for reducing the gadolinium exposure of returning patients. Small lesions proved, however, difficult to handle for the deep network, showing that full-dose injections remain essential for accurate first-line diagnosis in neuro-oncology.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Ammari S, Bône A, Balleyguier C, et al. Can Deep Learning Replace Gadolinium in Neuro-Oncology?: A Reader Study. Invest Radiol. 2022. PMID: 34324463. doi:10.1097/RLI.0000000000000811

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。